Q3 EPS Beats at $2.79 as Oncology Sales Jump 17%; New $1.5B Cost-Savings Plan
AZN sits 18% above its 52-week low of $153.413.
Summary
AstraZeneca beat on both lines: core EPS of $2.79 rose 19% at constant currency versus the $2.62 consensus, and revenue grew 7% to $16.21B. Oncology did the heavy lifting, up 17%, with Tagrisso at $2.09B ahead of the $2.01B expected and Imfinzi also above estimates. Management reaffirmed full-year 2026 guidance for mid-to-high single-digit revenue growth and low double-digit core EPS growth at constant rates, so the beat is not being funded by a guidance cut. Separately, the company launched a three-year program targeting $1.5B in annual pretax savings, mostly reinvested into the pipeline, at the cost of a one-time restructuring charge of up to $2B with most of the work done by end-2029. Shares rose 3.5% premarket. The read: the beat plus intact guidance supports the thesis, while the charge is a modest near-term earnings drag that buys a leaner cost base.
At the time of this announcement, AZN was trading at $180.60 on NYSE in the Life Sciences sector, with a market capitalization of approximately $270.5B. The 52-week trading range was $153.41 to $212.71. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Seeking Alpha.